Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.

ABSTRACT: NAD⁺ availability decreases with age and in certain disease conditions. Nicotinamide mononucleotide (NMN), a key NAD⁺ intermediate, has been shown to enhance NAD⁺ biosynthesis and ameliorate various pathologies in mouse disease models. In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging. Orally administered NMN was quickly utilized to synthesize NAD⁺ in tissues. Remarkably, NMN effectively mitigates age-associated physiological decline in mice. Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorate

SUBMITTER: Mills KF 

PROVIDER: S-EPMC5668137 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature